Finoriq research workspace
Oruka Therapeutics, Inc. (ORKA) News
Oruka Therapeutics, Inc. also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a. Review ORKA recent headlines, source links, and company news on Finoriq.
Company Snapshot
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
- Company
- Oruka Therapeutics, Inc. (ORKA)
- Ticker
- ORKA
- Market Cap
- $5.7B
- Latest Price
- $94.17
- Industry
- Diagnostics
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.